Bictegravir/Emtricitabine/Tenofovir Alafenamide
Sold as Biktarvy
Biktarvy is a once-daily single-tablet regimen used for HIV treatment (not for PrEP/prevention). It combines an integrase inhibitor (bictegravir) with two nucleoside reverse transcriptase inhibitors to suppress the virus to undetectable levels.
Boxed warning
Boxed warning (class effect of the NRTI component): lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogs. Also: severe acute exacerbation of hepatitis B has occurred in patients coinfected with HIV and HBV who discontinued this or similar products — hepatitis B status must be checked before stopping treatment, with close monitoring after discontinuation.
What it treats
Treatment of HIV-1 infection in adults and pediatric patients (weighing at least 14 kg) who have no prior antiretroviral treatment history, or to replace a stable current regimen. Biktarvy is FOR TREATMENT ONLY — it is not FDA-approved for PrEP (HIV prevention in HIV-negative people). Truvada and Descovy are the PrEP-approved options in this class.
Typical dosing
One tablet (50 mg bictegravir/200 mg emtricitabine/25 mg tenofovir alafenamide) by mouth once daily, with or without food. Take at the same time each day for consistent viral suppression.
Monitoring
Kidney function (creatinine/eGFR) before starting and periodically during treatment — tenofovir alafenamide is gentler on kidneys and bone than the older tenofovir disoproxil (TDF), but monitoring still applies. HIV viral load and CD4 count per your HIV care team's schedule. Screen for hepatitis B before starting — stopping Biktarvy in a patient with untreated hepatitis B can cause a dangerous flare.
Side effects
Common: diarrhea, nausea, headache. Serious (rare): lactic acidosis and severe liver problems (boxed-warning class effect for nucleoside analogs), immune reconstitution syndrome shortly after starting treatment, worsening of hepatitis B if present and untreated, kidney problems.
Interactions to know
Do not take with dofetilide (dangerous interaction with bictegravir). Certain anticonvulsants, rifampin, and St. John's wort can reduce effectiveness. Antacids/supplements containing polyvalent cations (calcium, iron, magnesium, aluminum) can reduce absorption — timing matters; ask your pharmacist.
Cost assistance programs
Gilead Advancing Access (manufacturer program) offers copay assistance for eligible commercially insured patients — many pay as little as $0 per month — and separate assistance pathways for uninsured/underinsured patients. Enroll or check eligibility at https://www.gileadadvancingaccess.com/. BetterBuyRx has no financial relationship with Gilead; we link to this because it is the official, free enrollment path.
Pregnancy & breastfeeding
Data on Biktarvy in pregnancy are more limited than for some other regimens; the HHS Perinatal HIV Guidelines should be consulted with your HIV care team, who will weigh viral suppression benefits against limited pregnancy-specific data. Do not stop or switch HIV treatment during pregnancy without your care team's guidance — untreated HIV poses a bigger risk to both parent and baby than most regimen choices.
Additional notes
Resistance considerations: as with any HIV regimen, missed doses increase the risk of resistance developing — strict daily adherence matters. Not recommended for patients with resistance to any component. Bone density: tenofovir alafenamide (in Biktarvy/Descovy) has a more favorable bone and kidney safety profile than the older tenofovir disoproxil fumarate (in Truvada) — relevant if switching between regimens.
Clinical content reviewed by the BetterBuyRx clinical team, on 2026-07-07.
Educational only. Not medical advice. Always confirm with your prescriber or pharmacist.